论文部分内容阅读
目的:比较控制性超促排卵(COH)过程中血清促黄体生成素(LH)低于正常时添加基因重组LH(rLH)或人绝经期尿促性腺激素(hMG)的效果。方法:选取因输卵管因素不孕行常规IVF-ET患者85例,全部采用长方案超促排卵,均给予基因重组促卵泡激素(rFSH)进行超促排卵,超促排卵第6日时如血清LH≥1.2 mIU/ml,继续用rFSH,作为对照组(rFSH组,n=37);如血清LH<1.2 mIU/ml,则随机纳入到hMG组(rFSH+hMG,n=30)或rLH组(rFSH+rLH,n=18)。结果:3组间在促性腺激素(Gn)用量、COH天数、获卵数、双原核率、优质胚胎率、临床妊娠率方面均无统计学差异。hMG组的rFSH用量显著低于rLH组(P<0.01)。结论:在黄体期降调节长方案超促排卵第6日,如血清LH<1.2 mIU/ml时,添加hMG或rLH,可获得与对照组(rFSH组)相似的临床结果。与添加rLH组相比,添加hMG组降低了rFSH用量,减少了患者的费用。
OBJECTIVE: To compare the effect of addition of recombinant human LH (rLH) or human menopausal ursonic gonadotropin (hMG) in patients with sub-normal serum luteinizing hormone (LH) during controlled ovarian hyperstimulation (COH). Methods: Eighty-five patients with conventional IVF-ET who had infertility due to fallopian tube were enrolled in this study. All patients received long-term regimen of ovulation induction. Both of them received rFSH for super-ovulation induction. On the 6th day, (RFSH group, n = 37); if serum LH <1.2 mIU / ml, they were randomly assigned into hMG group (rFSH + hMG, n = 30) or rLH group rFSH + rLH, n = 18). Results: There was no significant difference among the three groups in the amount of gonadotropin (Gn), COH days, number of oocytes retrieved, prokaryotic rate, high quality embryo rate and clinical pregnancy rate. The amount of rFSH in hMG group was significantly lower than that in rLH group (P <0.01). CONCLUSIONS: On the 6th day of ovariectomized long term regimen of luteal phase, such as serum LH <1.2 mIU / ml, hMG or rLH was added to obtain similar clinical results as the control group (rFSH group). Compared with adding rLH group, adding hMG group reduced rFSH dosage and reduced patient’s cost.